Mark Carlson
Mark Carlson
Scientist II at Organogenesis, Inc.
Verified email at
Cited by
Cited by
The importance of both fibroblasts and keratinocytes in a bilayered living cellular construct used in wound healing
AM Wojtowicz, S Oliveira, MW Carlson, A Zawadzka, CF Rousseau, ...
Wound repair and regeneration 22 (2), 246-255, 2014
The need for a public proteomics repository
JT Prince, MW Carlson, R Wang, P Lu, EM Marcotte
Nature biotechnology 22 (4), 471-472, 2004
Three‐dimensional tissue models of normal and diseased skin
MW Carlson, A Alt‐Holland, C Egles, JA Garlick
Current Protocols in Cell Biology 41 (1), 19.9. 1-19.9. 17, 2008
A map of human protein interactions derived from co‐expression of human mRNAs and their orthologs
AK Ramani, Z Li, GT Hart, MW Carlson, DR Boutz, EM Marcotte
Molecular systems biology 4 (1), 180, 2008
Drug-induced inhibition of the peripheral-type benzodiazepine receptor expression and cell proliferation in human breast cancer cells.
V Papadopoulos, A Kapsis, H Li, H Amri, M Hardwick, M Culty, ...
Anticancer research 20 (5A), 2835-2847, 2000
Fibroblasts derived from human embryonic stem cells direct development and repair of 3D human skin equivalents
Y Shamis, KJ Hewitt, MW Carlson, M Margvelashvilli, S Dong, CK Kuo, ...
Stem cell research & therapy 2, 1-12, 2011
Epigenetic and phenotypic profile of fibroblasts derived from induced pluripotent stem cells
KJ Hewitt, Y Shamis, RB Hayman, M Margvelashvili, S Dong, MW Carlson, ...
PLoS one 6 (2), e17128, 2011
Three-dimensional epithelial tissues generated from human embryonic stem cells
KJ Hewitt, Y Shamis, MW Carlson, E Aberdam, D Aberdam, JA Garlick
Tissue Engineering Part A 15 (11), 3417-3426, 2009
Chronic ulcerative stomatitis: evidence of autoimmune pathogenesis
MW Carlson, JA Garlick, LW Solomon
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and…, 2011
Quantitative gene expression assessment identifies appropriate cell line models for individual cervical cancer pathways
MW Carlson, VR Iyer, EM Marcotte
BMC genomics 8, 1-13, 2007
Epidermal Stem Cells Are Preserved During Commercial-Scale Manufacture of a Bilayered, Living Cellular Construct (Apligraf)
M Carlson, K Faria, Y Shamis, J Leman, V Ronfard, J Garlick
Tissue Engineering Part A 17 (3-4), 487-493, 2011
BIM-44058, a novel analog of PTHrP with enhanced bone building activity, but decreased calcium-mobilization potential
MD Culler, J Dong, Y Shen, J Taylor, L Carlile, T Sullican
J Bone Miner Res 16 (Suppl 1), M460, 2001
Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers
KL Jackson, RV Agafonov, MW Carlson, P Chaturvedi, D Cocozziello, ...
Cancer Research 82 (12_Supplement), ND09-ND09, 2022
The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth
M Huchet, D Demarquay, H Coulomb, P Kasprzyk, M Carlson, J Lauer, ...
Annals of the New York Academy of Sciences 922 (1), 303-305, 2000
IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents
AM Liberatore, H Coulomb, D Pons, O Dutruel, PG Kasprzyk, M Carlson, ...
Molecular cancer therapeutics 7 (8), 2426-2434, 2008
Development of an AchillesTAG degradation system and its application to control CAR-T activity
GK Veits, CS Henderson, A Vogelaar, SJ Eron, L Lee, A Hart, RW Deibler, ...
Current Research in Chemical Biology 1, 100010, 2021
P-325 Oral delivery of a single microbial strain, EDP1503, induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity
D McHale, L Francisco-Anderson, P Sandy, S Shariffudin, M Goldberg, ...
Annals of Oncology 31, S195, 2020
Monoclonal microbial EDP1503 to induce antitumor responses via gut-mediated activation of both innate and adaptive immunity
HA Gardner, S Kashyap, H Ponichtera, P Sandy, P Parameswaran, ...
J Clin Oncol 37 (15_suppl), e14241-e14241, 2019
An E-ring modified camptothecin, BN 80915, shows unusual stability and high activity both in vitro and in vivo
PG Kasprzyk, D Demarquay, L Lesueru-Ginot, M Carlson, J Lauer, ...
Proc AACR 40, 739, 1999
Abstract PS11-27: a phase I/II clinical trial of EDP1503 with pembrolizumab for triple-negative breast cancer
L Francisco-Anderson, S Shariffudin, H Gardner, P Sandy, M Goldberg, ...
Cancer Research 81 (4_Supplement), PS11-27-PS11-27, 2021
The system can't perform the operation now. Try again later.
Articles 1–20